, Tracking Stock Market Picks
Enter Symbol:
Teva Pharmaceutical Industries Limited (TEVA) [hlAlert]

up 12.54 %

Teva Pharmaceutical Industries Limited (TEVA) rated Buy with price target $66 by Maxim Group

Posted on: Monday,  Dec 22, 2014  9:25 AM ET by Maxim Group

Maxim Group rated Buy Teva Pharmaceutical Industries Limited (NYSE: TEVA) on 12/22/2014, when the stock price was $57.93.
Since then, Teva Pharmaceutical Industries Limited has gained 12.55% as of 09/01/2015's recent price of $65.20.
If you would have followed this Maxim Group's recommendation on TEVA, you would have gained 12.54% of your investment in 253 days.

Teva Pharmaceutical Industries Limited (Teva) is a global pharmaceutical company that develops, produces and markets generic drugs covering all treatment categories. The Company has a pharmaceutical business, whose principal products are Copaxone for multiple sclerosis and Azilect for Parkinson?s disease and respiratory products. Teva?s active pharmaceutical ingredient business provides vertical integration to Teva?s own pharmaceutical production and sells to third party manufacturers. The Company?s global operations are conducted in North America, Europe, Latin America, Asia and Israel. Teva has operations in more than 60 countries, as well as 38 finished dosage pharmaceutical manufacturing sites in 17 countries, 20 generic research and development centers operating mostly within certain manufacturing sites and 20 API manufacturing sites around the world. In January 2009, Phibro Animal Health Corporation completed the acquisition of the Abic Animal Health business from the Company.

At Maxim Group, our vision for equity research is to be a client’s first call for value-added research on companies not widely followed by Wall Street. Maxim’s premier niche is emerging-growth companies in a variety of sectors, including healthcare, technology, retail and others. As strong believers in fundamental research, our analysts utilize a “bottom up” approach to making investment recommendations. We combine rigorous financial analysis of specific companies and industries with due diligence that includes frequent consults with suppliers, customers, competitors and senior management. By applying these skills and techniques, we are able to offer our clients differentiated research.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
12/22/2014 9:25 AM Buy
57.93 66.00
as of 10/17/2014
1 Week down  -1.29 %
1 Month down  -2.34 %
3 Months down  -3.10 %
1 YTD up  18.80 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
11/10/2014 8:25 AM Buy
57.86 70.00
8/5/2014 12:00 AM Buy
52.78 62.00
4/30/2014 12:00 AM Hold
48.86 49.00
6/19/2013 8:25 AM Buy
39.48 56.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy